Corrigendum to "Encephalopathy in COVID-19 patients; viral, parainfectious, or both?" [eNeurologicalScic(Volume 21), December 2020, 100275].

[This corrects the article DOI: 10.1016/j.ensci.

Corrigendum to 'Encephalopathy in COVID-19 patients; viral, parainfectious, or both?' [eNeurologicalScic(Volume 21), December 2020, 100275].

[This corrects the article DOI: 10.1016/j.ensci.

Encephalopathy in COVID-19 patients; viral, parainfectious, or both?

We describe the clinical, laboratory and radiological features of 3 critically ill patients with COVID-19 who developed severe encephalopathy. The first patient did not regain consciousness when sedation was removed at the end of 2 weeks of intensive care. He had received treatment with convalescent plasma.

Anti-malarial landscape in Myanmar: results from a nationally representative survey among community health workers and the private sector outlets in 2015/2016.

Background: In 2015/2016, an ACTwatch outlet survey was implemented to assess the anti-malarial and malaria testing landscape in Myanmar across four domains (Eastern, Central, Coastal, Western regions). Indicators provide an important benchmark to guide Myanmar's new National Strategic Plan to eliminate malaria by 2030.

Methods: This was a cross-sectional survey, which employed stratified cluster-random sampling across four regions in Myanmar.